ArticleNeurologia medico-chirurgica2026
Outcomes of Postnatal Myelomeningocele Repair in a Japanese Single-center Cohort: A Comparison with the Management of Myelomeningocele Study Trial.
Article in Neurologia medico-chirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal surgery for myelomeningocele is not yet standard practice in Japan. To establish baseline data for the outcomes of standard postnatal care for patients eligible for fetal surgery, we compared the results from our large, single-institution cohort with those of the Management of Myelomeningocele Study trial's postnatal group. We retrospectively reviewed 65 patients who underwent postnatal myelomeningocele repair at our center between 2002 and 2021. In our cohort, the myelomeningocele lesion level was thoracic in 18% of patients, L1-L2 in 12%, and L3 or below in 69%. Key outcomes, including the rate of cerebrospinal fluid shunt placement at 12 months and ambulation status at 30 months, were compared to the published data from the Management of Myelomeningocele Study postnatal cohort. The rate of cerebrospinal fluid shunt placement in our cohort (88%) and ambulation rates at 30 months (28%) showed no statistically significant difference from the Management of Myelomeningocele Study postnatal group (83%, p = 0.39, and 20%, p = 0.29, respectively). Our cohort had a significantly lower rate of shunt infection (0% vs. 9%, p = 0.02). However, the rates of surgery for symptomatic Chiari II malformation (18% vs. 5%, p = 0.01) and for tethered cord syndrome (9% vs. 1%, p = 0.03) were significantly higher in our cohort. The outcomes of modern postnatal myelomeningocele repair at a major Japanese center are largely consistent with the international benchmark set by the Management of Myelomeningocele Study trial. This study provides an essential baseline of data that will be indispensable for counseling families and for the objective evaluation of fetal surgery as it is introduced in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.